Real-World Experience of Patient's Compliance and Clinical Outcomes for Trimodality Treatment for Esophageal Cancer: a Study from a Cancer Center in North-East India.

Preoperative chemoradiotherapy is a standard treatment for patients with locally advanced, resectable esophageal cancer. The treatment completion rates impact the survival outcomes (Eyck et al J Clin Oncol 39(18):1995-2004, 2021). Thus, we aimed to estimate the effect of neoadjuvant chemoradiotherapy (NACRT) in terms of treatment completion rates and survival in this subset of patients and bring out the clinical outcomes in that context. This was a retrospective study done at a tertiary cancer center in North-East India. The study period was from 1 January 2018 to 31 December 2021. We included patients diagnosed with locally advanced and resectable esophageal cancer (cT2-3NanyM0) involving the middle and/or lower thoracic esophagus and who were planned for trimodality treatment in the Joint Tumor Board. Out of the 82 patients who were planned for trimodality treatment, all were squamous cell carcinomas. We found that 54.9% of patients completed the entire trimodality treatment. The median age was 56 years (range 34 to 73 years). The male to female ratio was 59:23. Adverse events, of any grade, were seen in 76% of patients who received NACRT. Fatigue (66%) was the most common toxicity. The common hematologic toxicities were neutropenia and anemia (7.3% each). A total of 45 patients (54.9%) were able to complete all the three modalities of treatment. Transthoracic esophagectomy was the preferred approach (84.4%). The site of anastomosis was in the neck of all the patients. Anastomotic leak was seen in 17.7% of patients. Postoperative pulmonary and cardiac complications occurred in 31.1% and 8.9% of patients respectively. The 30-day mortality was 6.7% (three deaths). A pathological complete response was seen in 35.6% among patients who underwent an esophagectomy. R0 resection was achieved in 93.3% of patients. The median overall survival and disease-free survival were 19 months and 17 months respectively. The completion rate of trimodality treatment in the real-world scenario was found to be low in our study, the reasons for which need to be identified and effectively resolved. Oncological outcomes were similar to the published literature.

Control of carbon monoxide (CO) from automobile exhaust by a dealuminated zeolite supported regenerative MnCo2O4 catalyst.

We synthesized MnCo(2)O(4) catalyst with very high porosity on the surface of dealuminated zeolite molecular sieves (DAZMS) for CO oxidation under actual automobile conditions. The MnCo(2)O(4) catalyst was selected on the basis of preliminary DFT study using the software ADF BAND. The MnCo(2)O(4) catalyst had comparatively higher CO adsorption energy and very low oxygen vacancy formation energy. The synthesized MnCo(2)O(4)/DAZMS catalyst was characterized by XRD, XRF, BET, SEM, and Confocal Microscopy. The Confocal microscopic analysis revealed that porosity of the dealuminated zeolite surface was significantly enhanced after the catalyst loading process. The completely precious metal free and DAZMS-supported catalyst exhibited excellent CO oxidation ability with renewed activity for seven months under actual automobile conditions with reference to normal and cold start conditions. The synthesized MnCo(2)O(4)/DAZMS not only exhibited surprisingly high catalytic activity for CO oxidation at a temperature resembling a cold start period but was also sufficiently stable/active under actual automobile conditions and ambient conditions containing large amounts of CO,H(2)O,CO(2), and NO(x) at 155-715 °C. These significant results revealed the flexible use of the present catalyst system for a wide variety of automobiles from a small gasoline-fuelled vehicle to a large diesel-fuelled vehicle that may produce high CO-content exhaust.

Computational study of molecular electrostatic potential, docking and dynamics simulations of gallic acid derivatives as ABL inhibitors.

Chronic myeloid leukemia (CML), a hematological malignancy arises due to the spontaneous fusion of the BCR and ABL gene, resulting in a constitutively active tyrosine kinase (BCR-ABL). Pharmacological activity of Gallic acid and 1,3,4-Oxadiazole as potential inhibitors of ABL kinase has already been reported. Objective of this study is to evaluate the ABL kinase inhibitory activity of derivatives of Gallic acid fused with 1,3,4-Oxadiazole moieties. Attempts have been made to identify the key structural features responsible for drug likeness of the Gallic acid and the 1,3,4-Oxadiazole ring using molecular electrostatic potential maps (MESP). To investigate the inhibitory activity of Gallic acid derivatives towards the ABL receptor, we have applied molecular docking and molecular dynamics (MD) simulation approaches. A comparative study was performed using Bosutinib as the standard which is an approved CML drug acting on the same receptor. Furthermore, the novel compounds designed and reported here in were evaluated for ADME properties and the results indicate that they show acceptable pharmacokinetic properties. Accordingly these compounds are predicted to be drug like with low toxicity potential.